NCT07937696 — Nouscom NOUS-209 neoantigen vaccine trial
A Vaccine (Nous-209) for the Reduction of Colorectal Lesion Size in Patients With Lynch Syndrome
Registry record
| Registry ID | NCT07937696 ↗ |
|---|---|
| Lead sponsor | National Cancer Institute (NCI) |
| Collaborators | — |
| Phase | Phase 2 |
| Status | Not Yet Recruiting |
| Indication | Colorectal Carcinoma, EPCAM Lynch Syndrome, Lynch Syndrome, MLH1 Lynch Syndrome, MSH2 Lynch Syndrome, MSH6 Lynch Syndrome, PMS2 Lynch Syndrome |
| Enrollment | 55 participants (target) |
| Start date | 2027-04-27 |
| Primary completion | 2031-11-30 (est.) |
| Last registry update | 17 Nov 2026 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT07937696), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
Daily coverage of the modality, tumor type and players this study touches:
Related trials
FAQ
What phase is NCT07937696?
NCT07937696 (A Vaccine (Nous-209) for the Reduction of Colorectal Lesion Size in Patients With Lynch Syndrome) is registered on ClinicalTrials.gov as Phase 2, sponsored by National Cancer Institute (NCI).
Is NCT07937696 recruiting?
As of the 2026-11-17 registry update, NCT07937696 is listed as "Not Yet Recruiting". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT07937696?
The lead sponsor is National Cancer Institute (NCI).
What condition does NCT07937696 study?
The registered conditions are Colorectal Carcinoma, EPCAM Lynch Syndrome, Lynch Syndrome, MLH1 Lynch Syndrome, MSH2 Lynch Syndrome, MSH6 Lynch Syndrome, PMS2 Lynch Syndrome. Primary completion is listed as 2031-11-30 (estimated).
Are results available for NCT07937696?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT07937696.
Back to the full neoantigen vaccine trial tracker — 105 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.